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Abstract The transurethral resection in saline (TURis)
system was notified by the company Olympus Medical to
the National Institute of Health and Care Excellence’s
(NICE’s) Medical Technologies Evaluation Programme.
Following selection for medical technologies guidance, the
company developed a submission of clinical and economic
evidence for evaluation. TURis is a bipolar surgical system
for treating men with lower urinary tract symptoms due to
benign prostatic enlargement. The comparator is any
monopolar transurethral resection of the prostate (mTURP)
system. Cedar, a collaboration between Cardiff and Vale
University Health Board, Cardiff University and Swansea
University in the UK, acted as an External Assessment
Centre (EAC) for NICE to independently critique the
company’s submission of evidence. Eight randomised trials
provided evidence for TURis, demonstrating efficacy
equivalent to that of mTURP for improvement of symp-
toms. The company presented meta-analyses of key out-
come measures, and the EAC made methodological
modifications in response to the heterogeneity of the trial
data. The EAC analysis found that TURis substantially
reduced the relative risks of transurethral resection syn-
drome (relative risk 0.18 [95 % confidence interval
0.05–0.62]) and blood transfusion (relative risk 0.35
[95 % confidence interval 0.19–0.65]). The company pro-
vided a de novo economic model comparing TURis with
mTURP. The EAC critiqued the model methodology and
made modifications. This found TURis to be cost saving at
£70.55 per case for existing Olympus customers and cost
incurring at £19.80 per case for non-Olympus customers.
When an additional scenario based on the only available
data on readmission (due to any cause) from a single trial
was modelled, the estimated cost saving per case was
£375.02 for existing users of Olympus electrosurgery
equipment and £284.66 per case when new Olympus
equipment would need to be purchased. Meta-analysis of
eight randomised trials showed that TURis is associated
with a statistically significantly reduced risk of transure-
thral resection syndrome and a reduced need for blood
transfusion—two factors that may drive cost saving for the
National Health Service. The clinical data are equivocal as
to whether TURis shortens the hospital stay. Limited data
from a single study suggest that TURis may reduce the rate
of readmission after surgery. The NICE guidance supports
adoption of the TURis technology for performing transur-
ethral resection of the prostate in men with lower urinary
tract symptoms due to benign prostatic enlargement.
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Key Points for Decision Makers
The efficacy of transurethral resection in saline
(TURis) is equivalent to that of monopolar
transurethral resection of the prostate (mTURP) in
terms of improving lower urinary tract symptoms
due to benign prostatic enlargement.
TURis is associated with a reduced risk of
transurethral resection syndrome and reduced need
for blood transfusion in comparison with mTURP.
The clinical data are equivocal as to whether TURis
shortens the hospital stay in comparison with
mTURP.
The TURis system is likely to be cost saving for
hospitals that already buy mTURP consumables
from Olympus at the list price. TURis may incur a
cost for non-Olympus customers.
Data from one randomised study suggest that TURis
may substantially reduce the rate of readmission (due
to any cause) following surgery in comparison with
mTURP.
Clinical experts suggest that most hospitals replacing
their capital equipment for transurethral resection of
the prostate would opt for a bipolar system rather
than a monopolar system.
1 Introduction
The National Institute for Health and Care Excellence
(NICE) provides the Medical Technologies Evaluation
Programme (MTEP). MTEP provides guidance on medical
devices and diagnostic technologies to the National Health
Service (NHS) in England and supports the adoption of
technologies that improve clinical outcomes or the patient
experience and/or that result in cost savings [1]. The pro-
cess followed in MTEP is explained in the first publication
in this series [1]. This article summarises the External
Assessment Centre (EAC) report [2] and how it was used to
inform the NICE Medical Technology Guidance on the
transurethral resection in saline (TURis) system for trans-
urethral resection of the prostate (TURP) [3]. Cedar, the
EAC for this guidance, is a collaboration between Cardiff
and Vale University Health Board, Cardiff University and
Swansea University.
Olympus Medical, the company supplying TURis,
notified the technology to NICE.
2 Background to the Conditions and the Device
In May 2010, NICE published a clinical guideline
(NICE CG97) on lower urinary tract symptoms (LUTS),
defining LUTS as storage, voiding and post-micturition
symptoms affecting the lower urinary tract [4]. In men, the
most common cause is benign prostatic enlargement
(BPE). Age is an important risk factor for LUTS, and the
prevalence of LUTS increases as men get older. Bother-
some LUTS can occur in up to 30 % of men older than
65 years, who represent a large group potentially requiring
treatment [4].
Men with LUTS due to BPE may be managed by
watchful waiting if their symptoms are mild or moderate.
For bothersome symptoms, education and lifestyle advice,
or medical therapies are usually the first-line treatments.
Medical therapies include muscarinic receptor antagonists,
5-alpha-reductase inhibitors, alpha-1 blockers and vaso-
pressin analogues [5].
NICE CG97 recommends that clinicians should offer
surgery only if voiding symptoms are severe or if drug
treatment and conservative management options have been
unsuccessful or are not appropriate [4]. Patient choice,
prostate volume, anaesthetic risk, anticoagulant therapy
and the local availability of different surgical techniques
are relevant factors when surgery is considered for a patient
with LUTS [5]. TURP has been performed to treat LUTS
since the 1930s [6, 7] and is less invasive than open
prostatectomy. Despite the relatively recent emergence of
other surgical therapies, which include transurethral inci-
sion or stent, laser enucleation or vaporisation and micro-
wave ablation, TURP remains the mainstay surgical
technique to treat LUTS due to BPE [5]. While some
surgical treatments have restricted suitability according to
prostate size, TURP is a surgical treatment option for men
with all prostate sizes [4].
3 Decision Problem (Scope)
3.1 Population
The relevant population is adult men with LUTS presumed
secondary to BPE, in whom surgical intervention, most
commonly monopolar transurethral resection of the pros-
tate (mTURP), is indicated [8].
3.2 Comparator (Current Practice)
Standard TURP is a monopolar electrosurgical technique
(mTURP). The surgeon introduces a resectoscope through
the urethra, and a generator generates an electrical current,
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which is delivered to an active loop electrode or roller
electrode at the end of the resectoscope. The electrode
focuses current on the prostate tissue, enabling the surgeon
to cut away chips of tissue or coagulate bleeding blood
vessels. The current disperses through the patient’s body
and returns to the generator via a return electrode, which is
a conductive, adhesive pad, usually placed on the patient’s
thigh. The return electrode requires careful attention
because if it is not correctly adhered, burn injuries may
result [9]. Also, mTURP requires a non-conductive irri-
gation fluid to wash away the tissue chips and blood,
examples being solutions of glycine, mannitol or sorbitol.
These solutions are not isotonic with blood and may be
absorbed by the body during surgery. Fluid absorption may
lead to a rare but potentially serious condition called
transurethral resection (TUR) syndrome, characterised by
fluid overload and hyponatraemia. The incidence of TUR
syndrome is 0.5–8 %, with a reported mortality rate of
0.2–0.8 % [10].
Following surgery, the patient has a urinary catheter and
undergoes bladder irrigation for a few days to clear debris
and blood. Standard practice is to discharge patients when
the catheter is removed and the patient can pass urine
satisfactorily.
The scope for MTG23 states that any mTURP system
may be a comparator for TURis [8].
3.3 Intervention (the TURis System)
TURis is a bipolar system used to perform TURP and may
be used in the same patient group who undergo mTURP.
‘Bipolar’ means that the active and return electrodes are
both located within the resectoscope. Therefore, electrical
current is focused on the prostate tissue but does not dis-
perse through the patient’s body, and no externally placed
return electrode is required. In addition, there is no need for
a non-conductive irrigation fluid, and normal saline may be
used. Saline is nearly isotonic with blood, and the company
has claimed that a benefit of TURis is that the risk of TUR
syndrome is eliminated. Other claimed benefits include
improved coagulation during surgery, reduced surgical
blood loss and better visibility for the surgeon. TURis uses
higher generator energy settings than mTURP. Other
bipolar technologies exist but are outside of the guidance
scope [8].
3.4 Outcomes
The outcomes studied in the evaluation of TURis were:
• Incidence of TUR syndrome.
• Incidence of blood transfusion.
• Incidence of clot retention.
• Length of hospital stay.
• Time to catheter removal.
• Procedure time.
• Incidence of readmission due to haemorrhage.
• Incidence of urethral stricture and bladder neck
contracture.
• Incidence of repeat procedures due to incomplete
resection.
4 Review of Clinical and Economic Evidence
4.1 Clinical Effectiveness Evidence
4.1.1 Company’s Review of Clinical Effectiveness
Evidence
The company undertook a comprehensive literature search,
which identified a relatively large volume of evidence
within the scope, restricted to English-language papers and
English-language abstracts, as per MTEP procedure. The
company included 16 publications presenting data from
randomised studies comparing TURis with mTURP [6, 11–
25]. Of these, four publications were conference abstracts
from a single study [16–19] and two were Spanish-lan-
guage [11] or German-language [25] full papers with
English-language abstracts.
The company also included publications from observa-
tional studies [26–33]. Of these, three were full papers [29,
31, 33] and five were conference abstracts [26–28, 30, 32].
All but two observational studies [27, 29] had a comparator
for TURis, most often mTURP, but sometimes including
other surgical procedures.
The company undertook meta-analyses of randomised
trials (TURis versus mTURP) to present the clinical evi-
dence relevant to TURis and did not place great emphasis
on the data from the observational studies. The company
included a meta-analysis of clot retention, an outcome not
specified in the scope [8].
4.1.2 Critique of Company’s Clinical Evidence Submission
The EAC performed an independent literature search and
identified all of the evidence provided by the company,
plus three additional studies published as full papers: two
randomised trials comparing TURis with mTURP [34, 35]
and one observational study of TURis [36]. The EAC
agreed with the company’s focus on meta-analysis of
randomised studies and, having also reviewed data from
the observational studies, concluded that these did not
significantly add to the evaluation of TURis. The EAC
considered that eight randomised trials (published as 13
TURis System for TURP: NICE Guidance
papers [6, 12–15, 20–25, 34, 35]) were eligible for inclu-
sion in its analysis. Table 1 presents the characteristics and
published papers of each randomised study included in the
analysis by the EAC, and Table 2 presents the studies
excluded by the EAC.
The eight randomised trials (Table 1) all presented data
on the patient group and the comparison specified in the
scope. None of the studies were undertaken in the UK.
Most studies were similar in terms of baseline prostate size,
which ranged typically from 45 to 60 g. The first of two
studies from the same team in China had the largest
baseline prostate size of 78 g [13]. This study also had the
longest procedure times for both TURis (88 min) and
mTURP (105 min) [13], whereas most of the other studies
had average procedure times of\60 min.
The study sample sizes ranged from 40 to 550 subjects.
Many studies did not define a primary outcome measure.
Only three studies stated that patients were blinded to
treatment allocation [13, 14, 34]. Only one study stated that
assessors of outcome were blinded to allocation status and
that a sample size calculation was performed [34]. It is
therefore unknown whether most of the studies had ade-
quate statistical power to detect important differences in
many of the outcome measures. Five studies reported the
method used to randomly allocate subjects to treatment [6,
14, 15, 20, 21, 23, 29, 34]. No study reported that an
intention-to-treat analysis was performed. Therefore, the
eight included randomised trials [6, 12–15, 20–25, 34, 35]
carried some risk of bias but represented a substantial
volume of evidence of reasonable quality to inform the
evaluation.
Table 3 summarises the results of the company’s meta-
analyses. The company’s analysis did not demonstrate that
TURis statistically significantly reduced the risk of TUR
syndrome (relative risk [RR] 0.28 [95 % confidence
interval (CI) 0.08–1.02]) or clot retention (RR 0.63
[95 % CI 0.21–1.90]), though the risk of blood transfusion
was substantially reduced by TURis (RR 0.36 [95 % CI
0.16–0.80]). The company found that TURis did not sig-
nificantly shorten the procedure time (mean difference -
1.68 [95 % CI -4.18–0.8]) minutes) but concluded that
TURis shortened the time to catheter removal (mean dif-
ference -0.23 [95 % CI -0.38 to -0.08] days) and also
the hospital stay (mean difference -0.52 [95 % CI -0.74
to -0.30] days).
4.1.3 Additional Work Carried Out by the External
Assessment Centre
The EAC studied the methodology of the company’s meta-
analysis and reproduced the analyses with checks or
modifications as follows:
• Adding data from additional randomised trials identi-
fied by the EAC [34, 35].
• Removing data that were duplicated in the company’s
analysis, because of repeat publication [20, 23].
• Excluding non-peer-reviewed data available only in
abstracts, which did not enable critical appraisal [16–
19].
• Obtaining confirmation from a lead author that two
randomised studies conducted at the same centre were
separate patient samples [13, 14].
• Determining whether the data from non-English-lan-
guage papers [11, 25] were pivotal to the analyses
(MTEP procedure is to include such data only when
this criterion is met, and with translation by a proper
agency), with translation of one paper into English [25].
• Correcting data entry errors.
• For outcomes expressed as RRs, excluding studies with
zero events in both study arms, as this precluded RR
calculation [11, 14, 25].
• Excluding from the meta-analyses one outlying study
conducted in China, which generated heterogeneity for
two outcomes (hospital stay and time to catheter
removal), because the EAC considered that both
outcomes are driven by local practice, which may
differ between healthcare providers [13].
The results of the EAC’s meta-analyses are summarised
in Table 3, alongside those of the company.
The EAC analysis found that TURis significantly
reduced the risk of TUR syndrome (RR 0.18 [95 % CI
0.05–0.62]) and suggested that one case of TUR syndrome
was prevented for every 50 patients treated with TURis.
The EAC found that the risk of blood transfusion was
significantly reduced (RR 0.35 [95 % CI 0.19–0.65]),
suggesting that one case of transfusion was prevented for
every 20 patients treated with TURis. Like the company,
the EAC found no statistically significant reduction in clot
retention (RR 0.55 [95 % CI 0.26–1.15]) and virtually no
difference in procedure time (mean difference -1.36
[95 % CI -3.70 to 0.98] min) or time to removal of the
catheter (mean difference -0.09 [95 % CI -0.25 to 0.06]
days). In contrast to the company’s analysis, the EAC’s
analysis found no substantial reduction in the hospital stay
through the use of TURis (mean difference -0.19
[95 % CI -0.46 to 0.07] days).
The remaining outcome measures specified in the scope
were readmission for repeat procedures, healthcare-asso-
ciated infection, quality of life and device-related adverse
events.
The EAC performed a meta-analysis of the rate of repeat
procedures due to incomplete resection (Table 3) and
found no significant difference between TURis and
mTURP (RR 0.76 [95 % CI 0.42–1.40]). The EAC also
A. Cleves et al.
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undertook a meta-analysis of readmission due to haemor-
rhage (Table 3) and found little difference between the
groups (RR 0.53 [95 % CI 0.22–1.25]).
The EAC recorded data on infection, where available
from studies, and concluded that there was little difference
in infection rates between TURis and mTURP. Likewise,
studies that reported either quality of life or functional
urological measures after treatment suggested that TURis
and mTURP were equivalent [12–15, 29, 34].
Because of a concern over higher energy settings used in
TURis, the EAC undertook meta-analyses of the longer-
term complications of urethral stricture and bladder neck
contracture, and found no difference in risk between TURis
and mTURP (Table 3).
The company identified four adverse events from the US
Food and Drug Administration’s Manufacturer and User
Facility Device Experience (MAUDE) database [37] and
the Medicines and Healthcare Products Regulatory Agency
(MHRA) database [38]. The EAC identified an additional
13 adverse events from the same sources, but these sources
were prone to either duplication or under-reporting of
events, and the EAC could not establish that every adverse
event was related to TURis. The commonest adverse event
was breakage or degeneration of the electrode. Other
events were failure to coagulate, urethral burns, bladder
rupture and air embolism leading to cardiac arrest. Adverse
events should be considered in the context of those that
arise during mTURP.
4.2 Economic Evidence
4.2.1 Company’s Economic Submission
The company identified three economic studies [39–41],
and the EAC identified one additional study, which inclu-
ded an economic estimation [36], but these were not used
as evidence for TURis by the company or by the EAC,
because of low applicability to the scope.
The company provided a de novo economic model in
the form of a decision tree with an NHS perspective and
2013 prices. The model matched the scope in terms of the
population (men with LUTS secondary to BPE in whom
surgical intervention is indicated), intervention (TURis)
and comparator (mTURP). Patients entering the model
were treated either with TURis or with mTURP. The fol-
lowing complications were included in the base case: TUR
syndrome and blood transfusion. The time horizon of the
model was not defined, but it was designed to capture early
surgical complications.
No capital cost for mTURP was included, since mTURP
capital equipment was assumed to be already in place
under standard care. For TURis capital costs, the model
considered existing Olympus customers and non-Olympus
customers independently, since new customers would
require more new equipment, assumed to be three each of a
telescope, light guide, inner sheath and outer sheath (total
£26,715). Existing Olympus customers had some compo-
nents already, so their capital cost was £8,800. The model
did not consider the capital cost of the generator in any
instance, because generators are supplied to customers free
of charge as part of a contract to buy a volume of con-
sumables. The company assumed that three sets of TURis
capital equipment (excluding the generator) would suffice,
enabling up to three TURis operations to be carried out per
session, but no more, because the equipment needs to be
cleaned before re-use. A discount rate of 3.5 % was applied
to the capital equipment cost of TURis beyond the first
year.
In addition to the base case, the company included three
optional scenarios in the model:
1. Considering the cost of readmission due to clot
retention.
Table 2 Randomised studies of transurethral resection in saline (TURis) versus monopolar transurethral resection of prostate (mTURP)
excluded from the analysis by the External Assessment Centre (EAC)
Study Country Sample size Follow-up Comments
Abascal-
Junquera
[11]
Spain 45 men
TURis group: n = 24
mTURP group: n = 21
NR Spanish-language paper with English-language abstract; the
data were not pivotal to any meta-analysis, so the data
were excluded from the EAC report
Goh/Gulur
[16–19]
NR 210 patients were recruited and
randomised; the first 156 were followed
up with IPSSs and flow rates
TURis group: n = 110 (80 were followed
up)
mTURP group: n = 100 (76 were followed
up)
12 months Abstracts only; it is not clear for all outcomes whether they
were based on the entire sample (210 patients) or only the
156 patients who were followed up for 12 months
IPSS International Prostate Symptom Score, NR not reported
TURis System for TURP: NICE Guidance
T
a
b
le
3
S
u
m
m
ar
y
o
f
m
et
a-
an
al
y
se
s
o
f
ra
n
d
o
m
is
ed
tr
ia
ls
co
n
d
u
ct
ed
b
y
th
e
co
m
p
an
y
an
d
b
y
th
e
E
x
te
rn
al
A
ss
es
sm
en
t
C
en
tr
e
(E
A
C
)
O
u
tc
o
m
e
m
ea
su
re
C
o
m
p
an
y
’s
in
cl
u
d
ed
st
u
d
ie
s
C
o
m
p
an
y
’s
re
su
lt
E
A
C
’s
in
cl
u
d
ed
st
u
d
ie
s
E
A
C
’s
re
su
lt
s
T
U
R
sy
n
d
ro
m
e
A
b
as
ca
l-
Ju
n
q
u
er
a
[1
1
]
A
k
m
an
[1
2
]
C
h
en
(I
I)
[1
4
]
G
o
h
[1
7
]
M
ic
h
ie
ls
en
[2
1
]
R
o
se
[2
5
]
R
R
0
.2
8
(9
5
%
C
I
0
.0
8
–
1
.0
2
)
C
I
in
cl
u
d
es
n
u
ll
v
al
u
e
p
=
N
S
A
k
m
an
[1
2
]
C
h
en
(I
)
[1
3
]
F
ag
er
st
ro
m
[1
5
]
G
ea
v
le
te
[3
4
]
H
o
[3
5
]
M
ic
h
ie
ls
en
[2
1
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
R
R
0
.1
8
(9
5
%
C
I
0
.0
5
–
0
.6
2
)
O
v
er
al
l
ef
fe
ct
:
p
=
0
.0
0
6
H
et
er
o
g
en
ei
ty
:
v2
=
0
.2
0
,
d
f
=
5
,
p
=
1
.0
0
,
I2
=
0
%
A
R
R
=
-
0
.0
2
(9
5
%
C
I
-
0
.0
3
to
-
0
.0
1
)
N
N
T
=
5
0
(9
5
%
C
I
3
3
–
1
0
0
)
B
lo
o
d
tr
an
sf
u
si
o
n
A
k
m
an
[1
2
]
C
h
en
(I
I)
[1
4
]
F
ag
er
st
ro
m
[6
]
R
R
0
.3
6
(9
5
%
C
I
0
.1
6
–
0
.8
0
)
N
o
p
v
al
u
e
re
p
o
rt
ed
A
k
m
an
[1
2
]
C
h
en
(I
)
[1
3
]
C
h
en
(I
I)
[1
4
]
F
ag
er
st
ro
m
[6
]
G
ea
v
le
te
[3
4
]
H
o
[3
5
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
R
R
0
.3
5
(9
5
%
C
I
0
.1
9
–
0
.6
5
)
O
v
er
al
l
ef
fe
ct
:
p
=
0
.0
0
0
8
H
et
er
o
g
en
ei
ty
:
v2
=
0
.8
3
,
d
f
=
5
,
p
=
0
.9
7
,
I2
=
0
%
A
R
R
=
-
0
.0
5
(9
5
%
C
I
-
0
.0
7
to
-
0
.0
2
)
N
N
T
=
2
0
(9
5
%
C
I
1
4
–
5
0
)
C
lo
t
re
te
n
ti
o
n
A
k
m
an
[1
2
]
M
ic
h
ie
ls
en
[2
0
]
R
R
T
U
R
is
/m
T
U
R
P
0
.6
3
(9
5
%
C
I
0
.2
1
–
1
.9
0
)
p
=
N
S
A
k
m
an
[1
2
]
C
h
en
(I
I)
[1
4
]
G
ea
v
le
te
[3
4
]
H
o
[3
5
]
M
ic
h
ie
ls
en
[2
0
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
R
R
0
.5
5
(9
5
%
C
I
0
.2
6
–
1
.1
5
)
O
v
er
al
l
ef
fe
ct
:
p
=
0
.1
1
H
et
er
o
g
en
ei
ty
:
v2
=
2
.7
1
,
d
f
=
4
,
p
=
0
.6
1
,
I2
=
0
%
H
o
sp
it
al
st
ay
A
k
m
an
[1
2
]
C
h
en
(I
)
[1
3
]
M
ic
h
ie
ls
en
[2
3
]
M
ea
n
d
if
fe
re
n
ce
-
0
.5
2
(9
5
%
C
I
-
0
.7
4
to
-
0
.3
0
)
d
ay
s
p
=
0
.0
0
0
1
A
k
m
an
[1
2
]
M
ic
h
ie
ls
en
[2
3
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
M
ea
n
d
if
fe
re
n
ce
-
0
.1
9
(9
5
%
C
I
-
0
.4
6
to
0
.0
7
)
d
ay
s
O
v
er
al
l
ef
fe
ct
:
p
=
0
.1
6
H
et
er
o
g
en
ei
ty
:
v2
=
0
.0
1
,
d
f
=
1
,
p
=
0
.9
2
,
I2
=
0
%
T
im
e
to
ca
th
et
er
re
m
o
v
al
A
k
m
an
[1
2
]
C
h
en
(I
)
[1
3
]
M
ic
h
ie
ls
en
[2
3
]
M
ea
n
d
if
fe
re
n
ce
-
0
.2
3
(9
5
%
C
I
-
0
.3
8
to
-
0
.0
8
)
d
ay
s
A
k
m
an
[1
2
]
M
ic
h
ie
ls
en
[2
3
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
M
ea
n
d
if
fe
re
n
ce
-
0
.0
9
(9
5
%
C
I
-
0
.2
5
to
0
.0
6
)
d
ay
s
O
v
er
al
l
ef
fe
ct
:
p
=
0
.2
4
H
et
er
o
g
en
ei
ty
:
v2
=
1
.0
8
,
d
f
=
1
,
p
=
0
.3
0
,
I2
=
8
%
P
ro
ce
d
u
re
ti
m
e
A
k
m
an
[1
2
]
C
h
en
(I
I)
[1
4
]
F
ag
er
st
ro
m
[6
]
M
ic
h
ie
ls
en
[2
3
]
M
ea
n
d
if
fe
re
n
ce
-
1
.6
8
(9
5
%
C
I
-
4
.1
8
to
0
.8
1
)
m
in
u
te
s
A
k
m
an
[1
2
]
C
h
en
(I
I)
[1
4
]
F
ag
er
st
ro
m
[6
]
H
o
[3
5
]
M
ic
h
ie
ls
en
[2
3
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
M
ea
n
d
if
fe
re
n
ce
-
1
.3
6
(9
5
%
C
I
-
3
.7
0
to
0
.9
8
)
m
in
u
te
s
O
v
er
al
l
ef
fe
ct
:
p
=
0
.2
6
H
et
er
o
g
en
ei
ty
:
v
2
=
5
.0
0
,
d
f
=
4
,
p
=
0
.2
9
,
I2
=
2
0
%
A. Cleves et al.
T
a
b
le
3
co
n
ti
n
u
ed
O
u
tc
o
m
e
m
ea
su
re
C
o
m
p
an
y
’s
in
cl
u
d
ed
st
u
d
ie
s
C
o
m
p
an
y
’s
re
su
lt
E
A
C
’s
in
cl
u
d
ed
st
u
d
ie
s
E
A
C
’s
re
su
lt
s
R
ea
d
m
is
si
o
n
d
u
e
to
h
ae
m
o
rr
h
ag
e
N
A
N
A
F
ag
er
st
ro
m
[1
5
]
G
ea
v
le
te
[3
4
]
R
o
se
[2
5
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
R
R
0
.5
3
(9
5
%
C
I
0
.2
2
–
1
.2
5
)
O
v
er
al
l
ef
fe
ct
:
p
=
0
.1
5
H
et
er
o
g
en
ei
ty
:
v
2
=
4
.2
6
,
d
f
=
2
,
p
=
0
.1
2
,
I2
=
5
3
%
A
R
R
=
-
0
.0
4
(9
5
%
C
I
-
0
.0
7
to
-
0
.0
1
)
N
N
T
=
2
5
(9
5
%
C
I
1
4
–
1
0
0
)
U
re
th
ra
l
st
ri
ct
u
re
/b
la
d
d
er
n
ec
k
co
n
tr
ac
tu
re
(a
g
g
re
g
at
ed
o
u
tc
o
m
e)
N
A
N
A
A
k
m
an
[1
2
]
C
h
en
(I
I)
[1
4
]
F
ag
er
st
ro
m
[1
5
]
G
ea
v
le
te
[3
4
]
H
o
[3
5
]
M
ic
h
ie
ls
en
[2
4
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
R
R
1
.0
8
(9
5
%
C
I
0
.7
0
–
1
.6
9
)
O
v
er
al
l
ef
fe
ct
:
p
=
0
.7
2
H
et
er
o
g
en
ei
ty
:
v2
=
3
.1
0
,
d
f
=
5
,
p
=
0
.6
9
,
I2
=
0
%
U
re
th
ra
l
st
ri
ct
u
re
N
A
N
A
C
h
en
(I
I)
[1
4
]
F
ag
er
st
ro
m
[1
5
]
G
ea
v
le
te
[3
4
]
H
o
[3
5
]
M
ic
h
ie
ls
en
[2
3
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
R
R
1
.0
9
(9
5
%
C
I
0
.6
0
–
1
.9
7
)
O
v
er
al
l
ef
fe
ct
:
p
=
0
.7
7
H
et
er
o
g
en
ei
ty
:
v2
=
2
.1
2
,
d
f
=
4
,
p
=
0
.7
1
,
I2
=
0
%
B
la
d
d
er
n
ec
k
co
n
tr
ac
tu
re
N
A
N
A
C
h
en
(I
I)
[1
4
]
F
ag
er
st
ro
m
[1
5
]
G
ea
v
le
te
[3
4
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
R
R
0
.8
8
(9
5
%
C
I
0
.3
5
–
2
.2
0
)
O
v
er
al
l
ef
fe
ct
:
p
=
0
.7
9
H
et
er
o
g
en
ei
ty
:
v2
=
0
.6
9
,
d
f
=
2
,
p
=
0
.7
1
,
I2
=
0
%
R
ep
ea
t
p
ro
ce
d
u
re
d
u
e
to
in
co
m
p
le
te
re
se
ct
io
n
N
A
N
A
F
ag
er
st
ro
m
[1
5
]
G
ea
v
le
te
[3
4
]
M
ic
h
ie
ls
en
[2
0
]
F
ix
ed
-e
ff
ec
ts
m
o
d
el
:
R
R
0
.7
6
(9
5
%
C
I
0
.4
2
–
1
.4
0
)
O
v
er
al
l
ef
fe
ct
:
p
=
0
.3
8
H
et
er
o
g
en
ei
ty
:
v2
=
3
.5
9
,
d
f
=
2
,
p
=
0
.1
7
,
I2
=
4
4
%
A
R
R
ab
so
lu
te
ri
sk
re
d
u
ct
io
n
(T
U
R
is
m
in
u
s
m
T
U
R
P
),
C
I
co
n
fi
d
en
ce
in
te
rv
al
,
d
f
d
eg
re
es
o
f
fr
ee
d
o
m
,
m
T
U
R
P
m
o
n
o
p
o
la
r
tr
an
su
re
th
ra
l
re
se
ct
io
n
o
f
p
ro
st
at
e,
N
A
n
o
t
ap
p
li
ca
b
le
,
N
N
T
n
u
m
b
er
n
ee
d
ed
to
tr
ea
t,
N
S
n
o
n
si
g
n
ifi
ca
n
t,
R
R
re
la
ti
v
e
ri
sk
(T
U
R
is
/m
T
U
R
P
),
T
U
R
tr
an
su
re
th
ra
l
re
se
ct
io
n
,
T
U
R
is
tr
an
su
re
th
ra
l
re
se
ct
io
n
in
sa
li
n
e
TURis System for TURP: NICE Guidance
2. Including re-operations due to the initial procedure
being terminated prior to completion.
3. Assuming that TURis reduces the hospital stay by
1 day in comparison with mTURP.
The base case inputs for the model were drawn from
several sources. Clinical parameters were drawn from the
company’s meta-analysis. The difference in hospital stay
between TURis and mTURP was taken from the com-
pany’s meta-analysis, but the mean length of stay for
mTURP was taken from hospital episode statistics (HES)
data for 2012–2013 [42]. The additional resources required
for treating patients with TUR syndrome, as used by the
company, were based on a 2-day stay in a high-dependency
unit, followed by a 2-day stay in a general ward, utilising
the national schedule of reference costs for 2012–2013 [43,
44]. The resources required for a blood transfusion in the
company’s model were taken from a published study [45].
The cost of re-operation due to the initial procedure being
terminated prior to completion was calculated in the
company’s model as the cost of consumables plus the cost
of the hospital stay.
The company’s base case analysis showed that TURis is
cost saving in comparison with mTURP. For existing
Olympus customers, the saving per case was £133.63, and
for non-Olympus customers, it was £114.19. The company
conducted one-way deterministic sensitivity analysis for
ten input variables and found that TURis remained cost
saving across the range of values tested. The company also
performed probabilistic sensitivity analysis, whereby each
model parameter was assigned a statistical distribution and
the model was run for 1000 simulations, by randomly
sampling the distributions and calculating the results of the
model each time. TURis remained cost saving in almost all
of the simulations.
4.2.2 Critique of Economic Evidence
The key drivers of the company’s model were the reduction
in the hospital stay for TURis patients in comparison with
mTURP, the cost of a bed-day and the cost of mTURP
consumables. The reduction in the hospital stay of
0.52 days was based on the company’s meta-analysis, in
which a single study [13] introduced heterogeneity into the
data. After removing this study, the EAC found a differ-
ence in the hospital stay of 0.19 days (p = 0.16) and
considered this difference to be small in magnitude and not
statistically significant. However the committee considered
that the point estimate of a reduction in the hospital stay of
0.19 days should be used in the model.
The cost of mTURP consumables was estimated by the
company to be 50 % of the cost of TURis consumables
(£80.57 per case). The EAC considered that for a key
driver of the model, it is more appropriate to use an
accurate cost where this is available.
The EAC considered that the company had overesti-
mated the cost of blood transfusion, by including several
blood products (red blood cells, plasma, platelets and
cryoprecipitate). Clinical advisers confirmed that the EAC
proposal of 2.7 units of red blood cells alone was a rea-
sonable estimate for transfusion for mTURP patients.
The EAC considered that the company’s model did not
consider the case where non-Olympus customers perform
mTURP with their own capital equipment but sourcing
cheaper mTURP consumables independently via NHS
Supply Chain. The EAC modified the model to explore this
scenario.
4.2.3 External Assessment Centre’s Revisions
of the Company’s Economic Model
The four most significant modifications made to the com-
pany’s model by the EAC were:
1. Changing the cost of mTURP consumables in the base
case.
2. Changing the reduction in hospital stay in the base
case.
3. Changing the cost of blood transfusion in the base
case.
4. Modelling an additional scenario based on limited
evidence [15] of a reduction in readmission (due to any
cause) following TURis.
These are explained as follows. For existing Olympus
customers, the EAC changed the cost of mTURP con-
sumables from £80.57 to £137.75 per case on the basis of
Olympus price list prices. For non-Olympus customers
independently sourcing consumables for mTURP, the
consumables cost per case was changed from £80.57 to
£56.84 on the basis of NHS Supply Chain prices. Clinical
experts confirmed that this was realistic. The EAC changed
the reduction in the hospital stay in favour of TURis from
0.52 days to 0.19 days on the basis of its own meta-anal-
ysis (Table 3) and at the request of the committee. The
EAC changed the cost of blood transfusion from £920.40 to
£329 to reflect the cost of 2.7 units of packed red cells [45].
On the basis of its own meta-analyses, the EAC also
made minor modifications to the risk of TUR syndrome in
mTURP cases and the likelihood of blood transfusion
(Table 3).
On this basis, the EAC base case analysis found TURis
to be cost saving at £70.55 per case for Olympus customers
and cost incurring at £19.80 per case for non-Olympus
customers.
The EAC’s additional scenario considered the only
available randomised trial [15] that reported rates of
A. Cleves et al.
readmission (due to any cause) following TURis (5.1 %)
and mTURP (16.1 %). The platform for this analysis was
the company’s scenario of readmission due to clot reten-
tion, and the EAC used the company’s estimated cost of
readmission of £2781, based on an NHS reference cost for
admission with urological complications [43]. There is
uncertainty regarding this cost, which may not be accurate
for all causes of readmission. The effect on the EAC’s base
case was that TURis was strongly cost saving by £375.02
per case for Olympus customers and £284.66 per case for
non-Olympus customers. This result must be treated with
caution because of the uncertainty of the modelled cost and
because the rates of readmission due to any cause were
based on just one randomised trial [15] and were not
reported in the other randomised trials [12–14, 20–25, 34,
35].
5 NICE Guidance
5.1 Preliminary Guidance
The evidence submitted by the company and the EAC’s
report were presented to the Medical Technologies Advi-
sory Committee (MTAC), who produced the following
draft recommendations:
‘‘The case for adopting the transurethral resection in
saline (TURis) system for resection of the prostate is
supported by the evidence. Using bipolar diathermy with
TURis instead of a monopolar system avoids the risk of
transurethral resection syndrome and reduces the need for
blood transfusion. It may also reduce the length of hospital
stay and hospital readmissions’’.
‘‘Using the transurethral resection in saline (TURis) sys-
tem instead of monopolar transurethral resection of the
prostate (TURP) results in an estimated saving of £71 per
patient for hospitals that already use an Olympus monopolar
system and an estimated additional cost of £20 per patient for
other hospitals. The savings are driven by reductions in
length of hospital stay and consumable costs. However, there
is some evidence of a reduction in readmissions with the
TURis system compared with monopolar TURP. If this
evidence is included, using the TURis system results in an
estimated saving of £375 per patient for hospitals that
already use an Olympus monopolar system and an estimated
saving of £285 per patient for other hospitals.’’
5.2 Consultation Response
During the consultation period, NICE received 12 consul-
tation comments from four consultees (one manufacturer,
one External Assessment Centre, one specialist society and
one patient organisation). The comments concerned
terminology, numerical errors and whether TURis raised
new concerns in comparison with mTURP in three areas:
the incidence of dysuria following surgery, training
requirements for surgical teams and equity of access to
surgery for all men covered by the scope [8]. The com-
mittee’s responses provided reassurance that TURis did not
impose a substantial training requirement for surgical
teams and that equity issues were given full consideration
in the guidance. Four urologist expert advisors confirmed
to the committee that the incidence of dysuria was similar
following TURis and mTURP. There were therefore few
changes made in preparation of the final NICE guidance on
TURis.
6 Key Challenges and Learning Points
In contrast to many medical technologies, there was a
relatively large quantity of good-quality evidence for the
TURis technology. However, heterogeneity in the data led
to differences in interpretation. None of the studies were
from the UK, and differences in procedural measures, such
as the length of the hospital stay, may depend on local
practices.
In the UK, there are a number of procurement routes for
medical technologies: buying the device outright, leasing
the device and receiving the device free of charge as part of
an arrangement to purchase an agreed number of con-
sumables. If the device is purchased outright, the hospital
may choose to purchase suitable third-party consumables.
In addition, upgrading to a new system for performing a
given procedure may allow utilisation of compatible capital
equipment already in place if the hospital stays with the
existing provider. This saving would need to be considered
against whether the provider’s new system conveyed
advantages over similar systems from competitor provi-
ders. This assessment demonstrated that each of these
issues can have an important impact on the resource con-
sequences of adopting the new technology.
7 Conclusion
The evidence from eight randomised trials [6, 12–15, 20–
25, 34, 35] demonstrates that the efficacy of TURis is
equivalent to that of mTURP in terms of improving LUTS
due to BPE and is associated with a reduced risk of TUR
syndrome and reduced need for blood transfusion in
comparison with mTURP. The clinical data are uncertain
as to whether TURis shortens the hospital stay.
The NICE guidance supports the adoption of the TURis
technology for performing TURP in men with LUTS due to
BPE [3].
TURis System for TURP: NICE Guidance
Following critical appraisal and appropriate revisions to
the company’s base case economic analysis, TURis was
cost saving by £70.55 per case for existing Olympus cus-
tomers and cost incurring by £19.80 per case for non-
Olympus customers.
If data from a single randomised study [15], suggesting
that rates of readmission (due to any cause) are lower for
TURis than for mTURP, are repeatable in practice, then
TURis is strongly cost saving irrespective of the likely
purchasing arrangement in place. There is uncertainty in
this finding, as it is based on a single study [15], and further
data from randomised studies that measure any-cause
readmission would be useful.
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